Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
Open Access Journal of Clinical Trials · 2018
DOI: 10.2147/oajct.s155706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Access Journal of Clinical Trials, 2018. Verfasst von Tatsunori Shimoi und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Shimoi, T., Shimomura, A., Shien, T., Uemura, Y., Kato, H., Kitada, M., Toyama, T., Aihara, T., & Mukai, H. (2018). Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial). Open Access Journal of Clinical Trials. https://doi.org/10.2147/oajct.s155706
Vancouver
Shimoi T, Shimomura A, Shien T, Uemura Y, Kato H, Kitada M, et al. Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial). Open Access Journal of Clinical Trials. 2018. doi:10.2147/oajct.s155706
BibTeX
@article{Shimoi2018,
author = {Shimoi, Tatsunori and Shimomura, Akihiko and Shien, Tadahiko and Uemura, Yukari and Kato, Hiroaki and Kitada, Masahiro and Toyama, Tatsuya and Aihara, Tomohiko and Mukai, Hirofumi},
title = {Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)},
journal = {Open Access Journal of Clinical Trials},
year = {2018},
doi = {10.2147/oajct.s155706}
}
EUVIMED